Electrical properties of prostatic tissues: I. Single frequency admittivity properties.
OBJECTIVE
Electrical properties of the prostate may provide sufficient contrast for distinguishing malignant and benign formations in the gland. We evaluated how well these electrical properties discriminate cancer from noncancer tissues in the prostate.


METHODS
Electrical admittivity (conductivity and permittivity) was recorded at 31 discrete frequencies of 0.1 to 100 kHz from each of 50 ex vivo human prostates. A specifically designed admittivity probe was used to gauge these electrical properties from sectioned prostate specimens. The specific tissue area probed was marked to provide precise colocalization between tissue histological assessment and recorded admittivity spectra.


RESULTS
Adenocarcinoma, benign prostatic hyperplasia, nonhyperplastic glandular tissue and stromal tissue were the primary tissue types probed. Mean cancer conductivity was significantly less than that of glandular and stromal tissues at all frequencies (p <0.05), while mean cancer permittivity was significantly greater than that of all benign tissues at 100 kHz (p <0.0001). ROC curves showed that permittivity at 100 kHz was optimal for discriminating cancer from all benign tissues. This parameter had 77% specificity at 70% sensitivity and an ROC AUC of 0.798.


CONCLUSIONS
The contrast in electrical admittivity properties of different prostate tissues shows promise for distinguishing cancer from benign tissues. Sensitivity and specificity exceed those reported for current prostate specific antigen screening practices at low prostate specific antigen, making this an attractive addition to the clinical armamentarium for identifying prostate cancer.
Halter
Ryan J
RJ
Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire 03755, USA. ryan.halter@dartmouth.edu
Schned
Alan
A
Heaney
John
J
Hartov
Alex
A
Paulsen
Keith D
KD
D000230:Adenocarcinoma / Q000175:diagnosis / Q000503:physiopathology*; D003937:Diagnosis, Differential; D017097:Electric Impedance; D055724:Electrophysiological Phenomena; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D011467:Prostate / Q000502:physiology*; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000503:physiopathology*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000503:physiopathology*
Phys Med Biol. 1996 Nov;41(11):2251-69
8938025
Phys Med Biol. 2002 Jul 7;47(13):2189-202
12164581
Urol Nurs. 2007 Dec;27(6):481-9; quiz 490
18217530
Prostate. 1999 May 15;39(3):213-8
10334111
JAMA. 2005 Jul 6;294(1):66-70
15998892
Med Biol Eng Comput. 2002 Jan;40(1):29-33
11954705
J Natl Cancer Inst. 2007 Oct 17;99(20):1503-4
17925529
J Urol. 2000 May;163(5):1471-5
10751860
Physiol Meas. 2008 Jun;29(6):S111-23
18544804
Eur Urol. 2009 Feb;55(2):376-83
18359147
J Urol. 2008 Apr;179(4):1580-6
18295258
IEEE Trans Biomed Eng. 2007 Jul;54(7):1321-7
17605363
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Cancer. 2008 Apr 15;112(8):1718-25
18330908
J Urol. 2009 Oct;182(4):1608-13
19683743
BJU Int. 2006 Feb;97(2):222-3
16430616